The most recent WHO Classification of Tumours emphasizes the importance of biomarker testing in the diagnosis of brain tumors, yet nearly 70% of patients with brain tumors reported not understanding what biomarker testing is in a recent survey. As part of our MyTumorID campaign, we spoke with Keith Ligon, MD, PhD, who is the Chief of Neuropathology at Brigham and Women’s Hospital and Dana-Farber Cancer Institute (DFCI) and serves as the Director of the Center for Patient Derived Models at DFCI. His informative interview will help you better understand pathology and biomarker testing: https://lnkd.in/edBc8mZY #MyTumorID #NationalBrainTumorSociety
National Brain Tumor Society’s Post
More Relevant Posts
-
"Primary breast cancer by itself does not kill. It is the metastasis, especially breast to brain metastasis that is the ultimate demise of patients. At the USC brain tumor center we are tackling the biology of brain metastasis both in the laboratory and the clinical setting in order to discover better treatments and outcomes for patients living with this horrendous diagnosis."Josh Neman PhD, Scientific Director USC Brain Tumor Center #breastcancerawareness #breastcancerawarenessmonth #braincancer #metastaticbreastcancer #metastasis #metastaticcancer Keck Medicine of USC USC Norris Comprehensive Cancer Center Keck School of Medicine of the University of Southern California
To view or add a comment, sign in
-
Dr Luca Malorni’s research from the PYTHIA trial, unveiled at SABCS 2023, highlights serum thymidine kinase's role as a key biomarker in predicting outcomes for metastatic breast cancer patients. This pivotal study points to the potential of thymidine kinase dynamics to guide treatment strategies, independent of tumor genetics. Discover these vital insights. 👇 For all SABCS 2023 videos, find the link in the comments! #SABCS2023 #BreastCancerAwareness #InnovativeResearch
To view or add a comment, sign in
-
🚀 Zurich Accelerate - Diagnosis 🚀 Second Medical Opinion: Another key element is access to a second medical opinion. Here, an expert in the UK or internationally will carry out a comprehensive review of the customer’s diagnosis and proposed or existing treatment plan. This service can be used once per unique diagnosis of cancer, heart or neurological condition, or by those referred for a bone marrow transplant or a live-donor organ transplant. Precision Cancer Medicine: Customised treatment plans using the latest tumour profiling technology and comprehensive support to help you get the best results. - Not a one size fits all approach.
To view or add a comment, sign in
-
According to the National Cancer Institute, more than 1️⃣0️⃣8️⃣K women in the U.S. are expected to be diagnosed with a gynecological cancer in 2024. Our experts, who work on six sub specialties, recognize the uniqueness of each diagnosis. As the only NCI-designated cancer center in South Florida, we have the largest portfolio of clinical trials, the most advanced approaches to surgery and #CancerResearch. Every new #gynecologic cancer patient's case is presented at a #multidisciplinary tumor board that includes the input of medical, gynecologic and radiation oncologists, radiologists, pathologists and genetic counselors. This collaboration ensures an accurate, comprehensive diagnosis and the most targeted, individualized treatments. You don't have to face #GynecologicCancer alone. We're here to stand with 🙌. Learn more: https://loom.ly/j40NPzQ. #GynecologicCancerAwarenessMonth
To view or add a comment, sign in
-
Lung Cancer Drug Shrinks This Rare Tumor🔬 Chordomas are rare tumors of the brain and spine that have limited surgical and neuro-oncological treatments. Learn about potential new treatment from a clinical trial published in 2023.🧠🔍 🔹 Dr. Santosh Kesari - is one of “America’s Top Doctors” selected by Castle Connolly Medical Ltd. He is among the top 1% of neuro-oncologists and neurologists in the nation. Listen to the full episode on your favorite podcast platform.🎧 #MedicalBreakthroughs #CancerResearch #Chordomas #HopeForPatients"
To view or add a comment, sign in
-
March is Brain Tumour Awareness Month 📣 🧠 And we are passionate about bringing you the latest news & updates - take a look at this NEW: #ESMO2023 interview | The role of #liquidbiopsy in #braincancers 🇪🇸 🎥 Enrico Franceschi, MD, IRCCS Istituto delle Scienze Neurologiche di Bologna, discusses the importance of obtaining #liquidbiopsies in patients with #braintumors 💉 #Liquidbiopsy is fundamental in the treatment of many #cancers for assessing individual #cancerbiology and treatment options, but this is more difficult in #braintumors due to the limited delivery of #circulatingtumorDNA (#ctDNA) across the blood-brain barrier 🩸 🧠 Although #cerebrospinalfluid is a more suitable prognostic assessment tool in these cancers, it is harder to obtain, meaning novel methods of accessing #ctDNA and disrupting the blood-brain barrier are required💡 Take a look 👉 https://lnkd.in/dEHKcpc4 #Oncology #BrainTumourAwarenessMonth ESMO - European Society for Medical Oncology
To view or add a comment, sign in
-
Glioblastoma Awareness Day is a day dedicated to increasing general awareness of Glioblastoma, which accounts for accounts for more than half of all primary malignant brain tumors. It can strike men, women, and children of any age, background, or walks of life and the causes are largely unknown. Glioblastoma is one of the most aggressive and challenging forms of brain cancer, resulting in significant impacts on patients and their families. Read more here and find out how to support the National Brain Tumor Society: https://lnkd.in/e8JtRQbh Find the clinical evidence for MVASI® and Avastin®, indicated for the treatment of recurrent glioblastoma DRUGDOCS®. https://lnkd.in/eHYydu_i https://lnkd.in/eAsfkSHq #GBMDay #Glioblastoma #GBM #Mvasi #Avastin
To view or add a comment, sign in
-
Excited to share our recent publication in the New England Journal of Medicine (NEJM Group) for the "Clinical Implications of Basic Research" series! 📝 In this article, we discuss groundbreaking work by Goto et al., recently published in Nature, which describes a novel mechanism of immune evasion during early colorectal carcinogenesis. Our analysis dives into how these insights could translate into meaningful clinical applications, potentially shaping future strategies in colorectal cancer prevention and interception. Many thanks to Elizabeth Phimister for the opportunity to contribute to this dialogue and to everyone involved in the publication process! #NEJM #ClinicalImplicationsofBasicResearch #TranslationalMedicine
Reactivation of SOX17 Program as Immune-Evasion Mechanism in Early Colorectal Cancer Development | NEJM
nejm.org
To view or add a comment, sign in
-
November scientific article now available to download: From clinic to MDT in one week – speeding up the prostate cancer diagnostic pathway Author(s): Dr Harry Bardgett Hospital: Bradford Teaching Hospitals NHS Foundation Trust Since October 2021 cancer networks have been measured against the new Faster Diagnostic Standard (FDS), which states that a patient should have a diagnosis or exclusion of cancer within 28 days from referral. Prostate cancer diagnosis, especially since the universal implementation of multi-parametric MRI (mpMRI), has always been a challenge to the fast-track diagnostic process, as patients travel between departments in a linear fashion, with the next step only possible upon completion of the previous one. https://lnkd.in/enkaesia #RADMagazine #medicalimaging #healthcare #medical #radiotherapy #oncology #CT #MRI
To view or add a comment, sign in
-
Exploiting the gut microbiome for brain tumour treatment https://lnkd.in/dQH3DA4A CELL Lily Keane, John Cryan, Jack P. Gleeson (University College Cork) Increasing evidence suggests that the gut microbiome plays a key role in a host of pathological conditions, including cancer. Indeed, the bidirectional communication that occurs between the gut and the brain, known as the ‘gut–brain axis,’ has recently been implicated in brain tumour pathology. Here, the authors focus on current research that supports a gut microbiome–brain tumour link with emphasis on high-grade gliomas, the most aggressive of all brain tumours, and the impact on the glioma tumour microenvironment. They discuss the potential use of gut–brain axis signals to improve responses to current and future therapeutic approaches. The researchers highlight that the success of novel treatment strategies may rely on patient-specific microbiome profiles, and these should be considered for personalised treatment approaches. #microbiome #cancer #gutmicrobiome #gutbrainaxis #tumour #braincancer
To view or add a comment, sign in
8,370 followers